---
title: "Remember Stuff: A Dyadic-focused Technology to Support Persons With Alzheimer's Disease in the Community"
nct_id: NCT04626804
overall_status: COMPLETED
phase: NA
sponsor: Indiana University
study_type: INTERVENTIONAL
primary_condition: Anxiety
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04626804.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04626804"
ct_last_update_post_date: 2023-03-01
last_seen_at: "2026-05-12T07:28:36.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Remember Stuff: A Dyadic-focused Technology to Support Persons With Alzheimer's Disease in the Community

**NCT ID:** [NCT04626804](https://clinicaltrials.gov/study/NCT04626804)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Indiana University
- **Conditions:** Anxiety, Depression, Caregiver Burnout, Anxiety Generalized
- **Start Date:** 2020-10-27
- **Completion Date:** 2022-12-31
- **CT.gov Last Update:** 2023-03-01

## Brief Summary

Test the usability, perceptions and acceptability of a computer monitor for participant diagnosed with ADRD and their caregiver who will program the applications specifically for each individual to help them remember activities of daily living. Goal is to keep participants in their homes longer and delay the need for institutional care

## Detailed Description

Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. The research team (N. Fowler, PhD) will assess measures at baseline, 30 days, 60 days and 90 days. The primary outcome is a caregiver-assessed measure usability. Secondary measures include patient- assessed usability, and objective measures of frequency and type of use and computer literacy for both caregiver and the individual with ADRD22. Methods to collect user data (frequency, clicks, etc.) will be collected using tools developed in Aim 2. Desired outcome measures include (1) a mean score of \>80 ("Good") on the ten-item System Usability Scale (SUS) modified by IU investigators to accommodate older adults23; (2) a 80 percent acceptability rate on the Behavioral Intention 3-item scale; and, (3) at least 70 percent of participants using R/S a minimum of weekly. SUS is a validated ten-item scale (e.g., "Learning to use RememberStuff® was quick for me") using a five-point response scale (strongly disagree to strongly agree). Acceptance will be assessed as the mean score on a 3-item Satisfaction scale (e.g., "Rate your satisfied with RememberStuff®?"). This scale was adapted by IU Investigators for health IT and uses a seven-point response scale from 0 (not at all) to 6 (a great deal). Satisfaction is one of the canonical assessments for user acceptance of technology. SUS and Satisfaction questionnaires will be researcher-administered by study staff either face-to-face in the participant's homes, or via telephone. The mean and standard deviation for the composite SUS, acceptability rate and weekly usage will be calculated to a 90% confidence interval. Other secondary measures are adapted from Holden et al and are guided by the UTAUT221. Mean caregiver scores on the measures will also be compared to mean scores of the patient measures to examine congruence in usability and acceptability within the dyad.

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 95 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Patient Inclusion Criteria:

* achieve a Montreal Cognitive Assessment (MoCA) score of 6-17 (mild to moderate dementia)
* diagnosis of early Alzheimer's disease or related dementia or caregiver reports ADRD diagnosis (if community based recruitment)
* provide identification of a caregiver (living with or otherwise involved in the ongoing care of the person with ADRD)
* able to communicate in English
* able to provide informed consent

Patient Exclusion Criteria:

* lives in a nursing home or long term care facility or assisted living facility
* do not pass the MoCA with a score between 6-17
* unable to identify a caregiver
* is limited by severe arthritis or other condition in the use of his/her hands

Caregiver Inclusion Criteria:

* 21 years or older
* able to provide informed consent
* able to communicate in English

Caregiver Exclusion Criteria:

* under 21 years of age
* does not have access to a computer/device
* diagnosis of ADRD
* diagnosis of serious mental illness (i.e. schizophrenia)
```

## Arms

- **1 Test the usability, perceptions, and acceptability of R/S** (EXPERIMENTAL) — Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.

## Interventions

- **Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community** (OTHER) — testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias

## Primary Outcomes

- **Usability** _(time frame: through study completion, an average of 4 months)_ — Satisfaction and use of the monitor and apps using the Usability Scale, a validated 10-item scale sithe items suchs as "learning to use the calendar function was quick for me", using a 5 point response scale (0= strongly disagree to 5= strongly agree)

Usability Scale, a validated 10-item scale (e.g. "Learning to use Calendar function was quick for me" using a 5-point response scale (0=strongly disagree to 5= strongly agree)

## Secondary Outcomes

- **Acceptability** _(time frame: through study completion, an average of 4 months)_
- **Intention of Use** _(time frame: through study completion, an average of 4 months)_
- **Performance expectancy** _(time frame: through study completion, an average of 4 months)_
- **Computer literacy** _(time frame: through study completion, an average of 4 months)_

## Locations (1)

- Indiana University, Indianapolis, Indiana, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.indiana university|indianapolis|indiana|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04626804.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04626804*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*